Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



The Fertility Show





Genome sequencing method promises higher accuracy with less DNA

16 July 2012

By Daryl Ramai

Appeared in BioNews 665

Technology that relies on less DNA to more accurately sequence people's genomes has been unveiled by a US biotech company.

In a paper in the journal Nature, Complete Genomics outlines how its 'long fragment read' technology produces few errors - one per 10 million DNA base-pairs, or 600 errors in an entire human genome – while using less tissue than previously required.

The technique is particularly relevant to non-invasive genetic sequencing of fetuses, and could have applications for screening pre-implantation embryos generated during IVF treatment. Furthermore, the technique enables separate sequencing of both maternal and paternal chromosomes to determine the degree of penetrance of genetic conditions.

Dr Rade Drmanac, Complete Genomics' chief science officer, said that the Nature paper demonstrated a 'ten-fold increase in accuracy' and that the technology 'is unmatched by any high-sensitivity method currently available'.

The company's shares closed up 44 percent on the day the technology was unveiled, with nearly 9.4 million shares of its stock exchanging hands. This will come as welcome news to the company which announced in June that it was laying off 55 staff after the company's net loss of $20.2 million in the first quarter of the year.

Complete Genomics has found it hard to compete with Illumina, which has emerged as the clear front-runner in the burgeoning field of genomic sequencing. Added to this, the firm is currently defending two patent suits filed against it by its rival.

Talking to Forbes magazine, Complete Genomics' chief executive officer Clifford Reid admitted that 'in the research market our advantages are pretty limited. We have higher quality. But in the research market that doesn't matter very much. Researchers can work with lower quality data. That's really been a startling revelation to us that despite the community saying quality is everything quality really isn't everything'.

As a result, Complete Genomics has focused on the prospective clinical market. The company's statement accompanying the Nature paper includes a quote from George Church, professor of genetics at Harvard Medical School, claiming that 'in the not-too-distant future, failure to use [the kind of technology developed by Complete Genomics] when providing genomic diagnoses in patient care will be seen as unacceptably inaccurate'.

 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

20 October 2014 - by Sean Byrne 
Illumina has announced the first three companies in its Accelerator Programme, designed to help genomics start-ups as other sources of funding grow scarce... [Read More]
21 July 2014 - by Dr Sarah Testori 
Genetic Alliance UK held its annual conference to discuss and reflect on the advances in genomic sequencing and to ask (and answer) why is it important, and how can it help to improve disease treatment... [Read More]
08 October 2012 - by Paola Quattroni 
A computer-based platform which looks to greatly speed up genetic analysis of tumours has been unveiled in the USA. Currently such analysis can take up to eight weeks, the new platform promises to deliver results in just 47 seconds... [Read More]
10 September 2012 - by Emma Stoye 
Scientists have found that 80 percent of DNA in the human genome, previously thought to be of no use, have important functions... [Read More]

09 July 2012 - by Dr Lux Fatimathas 
US researchers have for the first time sequenced the genome of a fetus using only a blood sample from the mother. It is hoped this new form of non-invasive sampling could allow doctors to screen for a range of genetic diseases prenatally, with minimal risk to the fetus... [Read More]
30 April 2012 - by Ruth Saunders 
The standoff between Roche and Illumina, which provides services and equipment for genetic analysis, finally came to an end last week as the Swiss pharmaceuticals giant ended efforts for a hostile takeover bid... [Read More]
27 February 2012 - by Ayesha Jadoon 
A handheld device for sequencing DNA on the move has been unveiled by UK company Oxford Nanopore. The single-use MinION tool resembles a USB drive in size and shape, and the company hopes it will be put into routine use by clinicians and researchers alike... [Read More]
16 January 2012 - by Dr Zara Mahmoud 
A US biotechnology firm has unveiled an automated desktop DNA sequencer that can decode the sequence of the human genome in one day for as little as $1,000 (£650). Given its first public viewing at a consumer electronics show in Las Vegas, Life Technologies Corporation's Ion Proton sequencer uses microchips similar to those found in digital cameras... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
PET CONFERENCE
COMMERCIALISATION OF LIFE


Lord Robert Winston, Professor of Science and Society at Imperial College London and speaker at the Progress Educational Trust's conference 'The Commercialisation of Life', taking place in central London on Tuesday 2 December

London, 2 December
Click HERE for details

FREE EVENT
GENETIC CONDITIONS


'Genetic Conditions: How Should Your DNA Be Used in the 100,000 Genomes Project?', a FREE public event being organised by the Progress Educational Trust in central London on the evening of Thursday 6 November 2014

London, 6 November
Click HERE for details

Good Fundraising Code

Advertise your products and services HERE - click for further details